Metabolic effects of fluoxetine in obese menopausal women

Journal of Endocrinological Investigation

Volumn 23, Issue 5, 2000, Pages 280-286

  Bondi, M ^b   Menozzi, R ^b   Bertolini, M ^b   Venneri, M G ^b   Del Rio, Graziano ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b NONE

Author keywords

Expenditure; Fluoxetine; Glucose induced thermogenesis; Obesity; Resting energy

Indexed keywords

DEXFENFLURAMINE; FLUOXETINE; GLUCOSE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENERGY EXPENDITURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MENOPAUSE; METABOLISM; OBESITY; RANDOMIZED CONTROLLED TRIAL; THERMOGENESIS; WEIGHT REDUCTION;

EID: 0033945360     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343724     Document Type: Article

References (24)

1. Wilber J.F. Neuropeptides, appetite regulation, and human obesity. JAMA 1991, 266: 257-259.
2. Troiano R.P., Flegal K.M., Kuczmarsky R.J., Campbell S.M., Johnson C.L Overweight prevalence and trends for children and adolescents: the National Health and Nutrition Examination Survey, 1963 to 1991. Arch. Pediatr. Adolesc. Med. 1997, 149: 1085-1091.
3. Leibowitz S.F., Weiss G.F., Shor-Posner G. Medial hypothalamic serotonin in the control of eating behaviour. Pharmacol. Biochem. Behav. 1985, 23: 541-550.
4. Blundell J.E., Hill A.J. Serotoninergic modulation of the pattern of eating and the profile of hunger-satiety in humans. Int. J. Obes. 1987, 11 (Suppl. 3): 141-155.
5. Stark P., Hardison C.D. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorders. J. Clin. Psychiatry 1985, 46: 7-13.
6. Stark P., Fuller R.W., Wong D.T. The pharmacologic profile of fluoxetine. J. Clin. Psychiatry 1985, 46: 7-13.
7. Greeno C.G., Wing R.R. A double-blind placebo controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorders. Am. J. Clin. Nutr. 1996, 64: 267-273.
8. Visser M., Seidell J.C., Koppeschaar H.P.F., Smits P. The effect of fluoxetine on body weight, body composition and visceral fat accumulation. Int. J. Obes. 1993, 17: 247-253.
9. Ferguson J.M., Feighner G.P. Fluoxetine-induced weight loss in overweight non-depressed humans. Int. J. Obes. 1987, 11 (Suppl. 3): 163-170.
10. Levine L.R., Rosenblatt S., Bosomworth J. Use of a serotonine re-uptake inhibitor, fluoxetine, in the treatment of obesity. Int. J. Obes. 1987, 11 (Suppl. 3): 185-190.
11. Levine L.R., Enas G.G., Thompson W.L., Byyny R.L., Daver A.D., Kirby R.W., Kreindler T.G., Levy B., Lucas C.P. Use of fluoxetine, a selective serotonine uptake inhibitor, in the treatment of obesity: a dose response study. Int. J. Obes. 1989, 13: 635-645.
12. Bross R., Hoffer L.J. Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am. J. Clin. Nutr. 1995, 61: 1020-1025.
13. Stinson J.C., Murphy C.M., Andrews J.F., Tomkin G.H. An assessment of the thermogenic effects of fluoxetine in obese subject. Int. J. Obes. 1992, 16: 391-395.
14. Pohelman E., Goran M.I., Gardner A.W., Ades P.A., Arciero P.J., Katzman-Rooks S.M., Montgomery S.M., Toth M.J., Sutherland P.T. Determinants of decline in resting metabolic rate in aging females. Am. J. Physiol. 1993, 264: E450-E455.
15. Gardner A.W., Pohelman ET. Physical activity is a significant predictor of body density in middle-aged and older males. Am. J. Clin. Nutr. 1993, 57: 8-14.
16. Webb P. 24-hours energy expenditure and the menstrual cycle. Am. J. Clin. Nutr. 1986, 44: 614-619.
17. Mateux P., Ducros F., Bourque J., Garon J., Chiasson J.L. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int. J. Obes. 1997, 21: 97-102.
18. Darga L.L., Carrol-Michals L., Botsford S.J., Lucas C.P. Fluoxetine's effect on weight loss in obese subjects. Am. J. Clin. Nutr. 1991, 54: 321-325.
19. Mansell P.I., Macdonald I.A. Reappraisal of the Weir equation for calculation of metabolic rate. Am. J. Physiol. 1990, 27: R1347-R1354.
20. Gray D.S., Fujioka K., Dewine W., Bray G.A. Fluoxetine treatment of the obese diabetic. Int. J. Obes. 1992, 16: 193-198.
21. O'Kane M., Wiles P.G., Wales J.K. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabetic Med. 1994, 11: 105-110.
22. Chiasson L., Law D.C.W., Leiter L.A., Tildesley H.D., Birmingham C.L., Ekoe J.M., Hamet P., et al. Fluoxetine has potential in obese NIDDM-multicentre Canadian trial. Diabetes 1989, 38: 154A.
23. Wise S.D. Clinical studies with fluoxetine in obesity. Am. J. Clin. Nutr. 1992, 55: 1815-1845.
24. Aronoff G.R., Bergstrom R.F., Pottratz S.T., Sloan R.S., Wolen R.L., Lemberger L. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin. Pharmacol. Ther. 1984, 36: 138-144.